Skip to main content

Table 3 Concomitant therapies

From: Clinical efficacy and tolerability of an immune-stimulant* constituted by inactivated bacterial bodies in the prophylaxis of infectious episodes of airways: a double blind, placebo-controlled, randomized, multicentre study

    Placebo Bacterial lysate p
Antibiotics No Count 57 (64.8%) 55 (61.1)  
  Yes Count 31 (35.2) 35 (38.9)  
Anti-inflammatory drugs No Count 53 (60.2) 56 (62.2) 0.785
  Yes Count 35 (39.8) 34 (37.8) (N.S.)
Antibiotics and anti-inflammatory drugs No Count 68 (77.3) 67 (74.4) 0. 659
  Yes Count 20 (22.7) 23 (25.6) (N.S.)
Bronchodilators No Count 76 (86.4) 79 (87.8) 0. 659
  Yes Count 12 (13.6) 11 (12.2) (N.S.)